

# Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US05/009759

International filing date: 23 March 2005 (23.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US  
Number: 60/556,281  
Filing date: 24 March 2004 (24.03.2004)

Date of receipt at the International Bureau: 25 April 2005 (25.04.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland  
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

1309242

# THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

*April 18, 2005*

**THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.**

**APPLICATION NUMBER: 60/556,281**

**FILING DATE: *March 24, 2004***

**RELATED PCT APPLICATION NUMBER: *PCT/US05/09759***



Certified by

Under Secretary of Commerce  
for Intellectual Property  
and Director of the United States  
Patent and Trademark Office

Please type a plus sign (+) inside this box → ☒

PTO/SB/16 (8-00)

Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**PROVISIONAL APPLICATION FOR PATENT COVER SHEET**

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

INVENTOR(S)					
Given name (first and middle (if any))		Family Name or Surname		Residence (city and either State or Foreign Country)	
May		Han		Brookline, MA	
<input type="checkbox"/> Additional inventors are being named on the ___ separately numbered sheets attached hereto					
TITLE OF THE INVENTION (280 characters max)					
METHODS FOR MEASURING ENZYME ACTIVITIES IN CELLS, BLOOD, TUMORS AND TISSUES					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input type="checkbox"/> Customer Number		<input type="text" value="1473"/>		<input type="text" value="Place Customer Number Bar Code Label here"/>	
<input checked="" type="checkbox"/> Firm or Individual Name		Fish & Neave Barbara A. Ruskin			
Address		1251 Avenue of the Americas			
Address					
City		New York	State	New York	ZIP 10020
Country		U.S.A.	Telephone	212-596-9000	Fax 212-596-9090
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification		Number of Pages <input type="text" value="21"/>		<input type="checkbox"/> CD(s), Number <input type="text" value=""/>	
<input checked="" type="checkbox"/> Drawing(s)		Number of Sheets <input type="text" value="12"/>		<input type="checkbox"/> Other (specify) <input type="text" value=""/>	
<input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.				FILING FEE AMOUNT (\$)	
<input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees					
<input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number:		<input type="text" value="06-1075"/>		<input type="text" value="\$80.00"/>	
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____					

Respectfully submitted,

SIGNATURE

*Barbara Ruskin*

Date

TYPED or PRINTED NAME

Barbara A. Ruskin

REGISTRATION NO.

(if appropriate)

Docket Number:

TELEPHONE

**USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT**

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

Express Mail No. EV132198435US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PROVISIONAL PATENT APPLICATION

Applicant : May Han

For : METHODS FOR MEASURING ENZYME ACTIVITIES IN CELLS,  
BLOOD, TUMORS AND TISSUES

Mail Stop Provisional Application  
Hon. Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

"EXPRESS MAIL" mailing label number EV 132198435 US


Date of Deposit: March 24, 2004

I hereby certify that this certification and the following  
papers and fees:

1. Provisional Application Cover  
Sheet (in duplicate);
2. Specification (21 pages);
3. ~~Twelve~~ (12) Sheets of Drawings;
4. Print EFS;
5. Check in the amount of \$80.00; and
6. Postcard receipt.

are being deposited with the United States Postal Service "Express  
Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the  
date indicated above and are addressed to Mail Stop PROVISIONAL  
PATENT APPLICATION, Hon. Commissioner for Patents, P.O. Box 1450,  
Alexandria, VA 22313-1450.

Name: \_\_\_\_\_

  
Claire J. Saintil-van Goodman

**METHODS FOR MEASURING ENZYME ACTIVITIES IN CELLS, BLOOD,  
TUMORS AND TISSUES**

**FIELD OF THE INVENTION**

[0001] The invention is directed to improved and high through-put methods for  
5 measuring the activities of enzymes involved in oxidative and non-oxidative  
pentose phosphate pathways and other thiamine pyrophosphate containing  
enzymes which are commonly elevated in tumor cells. The assays of the  
invention are useful for optimizing therapeutic dosing and scheduling of drugs  
acting on the pentose phosphate pathways by sampling and monitoring enzymatic  
10 levels in a treated patient over time. Moreover, the assays are useful for  
identifying and characterizing compounds having potentially beneficial therapeutic  
effects.

**BACKGROUND OF THE INVENTION**

15 [0002] Transketolase, a key player in non-oxidative pentose phosphate pathways,  
shunts carbon away from glycolytic intermediates and forms ribose-5-phosphate  
required for nucleic acid biosynthesis. Because of its role in ribose synthesis -- and  
thus RNA and DNA synthesis -- transketolase may also play a critical role in  
regulating cell proliferation. Indeed, non-oxidative pentose phosphate pathways  
20 are often stimulated in situations of active cell proliferation, such as in tumor cells.

[0003] Transketolase (TK) utilizes thiamine (vitamin B<sub>1</sub>), converted to thiamine pyrophosphate (TPP) by thiamine pyrophosphokinase, as its co-factor for catalysis. TPP is the active form of the vitamin. Once bound, the TPP co-factor is inaccessible to the solvent and has no appreciable off-rate. Other TPP utilizing enzymes include alpha-ketoglutarate dehydrogenase (kGDH) and pyruvate dehydrogenase (PDH). Glucose-6-phosphate dehydrogenase (G6PDH) can also produce ribose via an oxidative pathway with concurrent generation of two molecules of NADPH. Proper monitoring of these key enzymes would provide a useful indication of the state of cell proliferation and cell growth in tumors.

10 [0004] Compounds that mimic the transketolase co-factor TPP can be potent and long-lasting inhibitors for the transketolase enzyme. The slow off-rate of TPP mimetics from transketolase makes them behave much like irreversible inhibitors. This property provides a convenient enzymatic assay for measuring inhibition of transketolase and TPP utilizing enzymes in blood, tumors and tissues after a dosing regimen.

15 [0005] It would be highly desirable to have improved diagnostic assays with quicker and greater accuracy and/or sensitivity for measuring the activity of transketolase as well as of the other key enzymes of the pentose phosphate pathways (i.e. G6PDH and other TPP utilizing enzymes; PDH and kGDH). Such an assay could also be used as a tool for assessing the potency and selectivity of specific anti-cancer treatments acting on pentose phosphate pathways.

20

#### SUMMARY OF THE INVENTION

[0006] The invention provides improved methods for measuring TK, kGDH, PDH and G6PDH activities, e.g., in cultured cells, blood, tumors and other tissues using fluorescence. The increased sensitivity of this fluorescence assay, which can be performed on cell lysates, significantly improves the assays of the present invention over enzymatic assays that monitor absorption. Accordingly, assays of the invention are useful for drug discovery, as well as for preclinical and clinical development of anti-cancer therapeutics and for determining drug dosing and scheduling in the clinic.

25

30

## BRIEF DESCRIPTION OF THE DRAWINGS

- [0007] **Figure 1:** An enzymatic reaction for transketolase in the non-oxidative pentose phosphate pathway. Transketolase activity is monitored by GAPDH-catalyzed conversion of NAD to NADH, resulting in the production of fluorescent NADH,
- [0008] **Figure 2:** The enzymatic activities of transketolase (TK) in blood (grey bars) and spleen (black bars) and alpha-ketoglutarate dehydrogenase (kGDH) in brain (white bars) after a single dose of N3-pyridyl thiamine (N3PT) in mice (100 mg/kg, i.p.) from 0 hr to 120 hr after dosing.
- [0009] **Figure 3:** TK activity in various organs (tumor, blood, brain, heart, kidney, liver, lung, spleen) after 11 days of a bi-daily 100 mg/kg dosing treatment with N3PT (white bars), oxythiamine (black bars), or vehicle (grey bars).
- [0010] **Figure 4:** kGDH activity in various organs (tumor, blood, brain, heart, kidney, liver, lung, spleen) after 11 days of a bi-daily dosing treatment with N3PT (white bars), oxythiamine (black bars), or vehicle (grey bars).
- [0011] **Figure 5:** G6PDH activity in various organs (tumor, blood, brain, heart, kidney, liver, lung, spleen) after 11 days of a bi-daily dosing treatment with N3PT (white bars), oxythiamine (black bars), or vehicle (grey bars).
- [0012] **Figure 6:** TK activity in various tested cell lines with (HCT116-TK, HT1080-TK) and without (HCT116, HT1080, DLD-1, HuCa25 (22Rv1)) over expressed TK. A bold horizontal line designates the detection limit. TK activity is plotted as the detected fluorescence (FU/min) as a function of the number of cells.
- [0013] **Figure 7:** kGDH activity with 200  $\mu$ M TPP in various tested cell lines with and without (HCT116, HCT116-TK, HT1080, HT1080-TK, DLD-1, HuCa25 (22Rv1)) over expressed TK. kGDH activity is plotted as the detected fluorescence (FU/min) as a function of the number of cells.
- [0014] **Figure 8:** G6PDH activity in various tested cell lines with (HCT116-TK, HCT 1080-TK) and without (HCT116, HT1080, DLD-1, HuCa25 (22Rv1)) over expressed TK. G6PDH activity is plotted as the detected fluorescence (FU/min) as a function of the number of cells.
- [0015] **Figure 9:** TK activity in various cell lines expressed as percentage enzymatic activity (the slope of initial linear range) of control wells that were not

treated with compounds. The values (y) were plotted as a function of the log concentration (micromolar) (x) and fitted to a sigmoidal dose-response curve.

[0016] **Figure 10:** Inhibition of TK and kGDH by N3PT in treated cells, expressed as percentage inhibition as a function of the log of compound concentration (micromolar).

[0017] **Figure 11:** Competitive inhibition of TK by N3PT in treated cells with increasing doses of thiamine, expressed as percentage enzymatic activity (the slope of initial linear range) of control cells that were not treated with compounds. The values (y) were plotted as a function of the log concentration (x) and fitted to a sigmoidal dose-response curve.

[0018] **Figure 12:** Competitive inhibition of TK by N3PT, expressed as relative mean transketolase activity as a function of the log of N3PT dose (micromolar) at days 2, 3, 5 and 7. Cells were treated with N3PT for two days after plating (day 2) then washed out and activity was monitored thereafter.

## DETAILED DESCRIPTION OF THE INVENTION

[0019] Unless otherwise defined herein, scientific and technical terms used in connection with the present invention shall have the meanings that are commonly understood by those of ordinary skill in the art to which this invention pertains. Further, unless otherwise required by context, singular terms shall include pluralities and plural terms shall include the singular.

[0020] The methods and techniques of the present invention are generally performed according to conventional methods well-known in the art and as described in various general and more specific references that are cited and discussed throughout the present specification unless otherwise indicated. See, e.g., Sambrook *et al.*, *Molecular Cloning: A Laboratory Manual*, 2d ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989); Ausubel *et al.*, *Current Protocols in Molecular Biology*, Greene Publishing Associates (1992, and Supplements to 2002); Harlow and Lane, *Antibodies: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1990); Worthington Enzyme Manual, Worthington Biochemical Corp. Freehold, NJ; *Handbook of Biochemistry: Section A Proteins*, Vol I 1976 CRC Press; *Handbook of Biochemistry: Section A Proteins*, Vol II 1976 CRC Press; Bast *et al.*, *Cancer*



*Medicine*, 5th ed., Frei, Emil, editors, BC Decker Inc., Hamilton, Canada (2000); Lodish et al., *Molecular Cell Biology*, 4th ed., W. H. Freeman & Co., New York (2000); Griffiths et al., *Introduction to Genetic Analysis*, 7th ed., W. H. Freeman & Co., New York (1999); Gilbert et al., *Developmental Biology*, 6th ed., Sinauer Associates, Inc., Sunderland, MA (2000); and Cooper, *The Cell - A Molecular Approach*, 2nd ed., Sinauer Associates, Inc., Sunderland, MA (2000).

5 [0021] The nomenclatures used in connection with, and the laboratory procedures and techniques of, molecular and cellular biology, microbiology, genetics, protein and nucleic acid biochemistry and hybridization, enzymology and  
10 medicinal and pharmaceutical chemistry described herein are those well known and commonly used in the art.

[0022] All publications, patents and other references mentioned herein are incorporated by reference in their entirety.

[0023] The following terms, unless otherwise indicated, shall be understood to  
15 have the following meanings:

[0024] As used herein, the term “transketolase” or “TK” refers to a key enzyme in the non-oxidative pentose phosphate pathway whose activity can be measured by the reaction depicted in Figure 1.

[0025] As used herein, the term “N3PT” or “N3-pyridyl-thiamine” refers to 3-  
20 [(2-amino-6-methyl-3-pyridinyl)methyl]-5-(2-hydroxyethyl)-4-methyl thiazolium.

[0026] As used herein, the term “activity” refers to a process or action of excitation or inhibition, and encompasses any specific activity of the factor in question (e.g., specific binding to one or more other cellular factors, and enzymatic activity when referring to enzymes, such as TK and other pentose phosphate and  
25 TPP utilizing enzymes).

[0027] As used herein, the term “pentose phosphate pathways” refers to both oxidative and non-oxidative forms of the pathway.

[0028] As used herein, the term “tumor” refers to either a heterogeneous tumor sample from a patient that contains a mass of tumorigenic cells and non-  
30 transformed normal cells, or to tumorigenic cells or tumor-derived cells (extracted from a tumor in an animal and cultured separately from the tumor either in vitro or in vivo), or cell lines developed from any of the above. The term encompasses

both hard and soft tumors that contain primary or metastatic tumorigenic cells associated with a malignancy. Examples include but are not limited to hematopoietic malignant cells (e.g., lymphomas, leukemias) and other malignant masses derived from specific organs (e.g., fibrosarcomas, adenocarcinomas, hepatomas, and melanomas).

[0029] As used herein, the term “drug treatment” refers to the general act of administering or applying a drug to a patient for a disease or injury. This act can include but is not limited to the general manipulation and management of factors such as the dosing, concentration and scheduling of the drug regimen so applied.

10 [0030] As used herein, the term “TPP mimetic” or “TPP mimetic drug” refers to a compound that is similar in both structure and function to a known compound or class of compounds which inhibit thiamine pyrophosphate utilizing enzymes.

[0031] As used herein, the term “tumor-derived cell” refers to a cell extracted from a tumor in an animal which has been cultured separately from the tumor, in vitro or in vivo.

[0032] As used herein, the term “patient” refers to an animal or a human.

[0033] Exemplary methods and materials are described below, although methods and materials similar or equivalent to those described herein can also be used in the practice of the present invention and will be apparent to those of skill in the art. In case of conflict, the present specification, including definitions, will control. The materials, methods, and examples are illustrative only and not intended to be limiting.

20 [0034] Throughout this specification and claims, the word “comprise” or variations such as “comprises” or “comprising”, will be understood to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.

#### Assays of the Invention

30 [0035] The assays and methods of the present invention measure the enzymatic activities of TPP utilizing enzymes including enzymes involved in the pentose phosphate pathways. TK activity for example, is known to be elevated in

tumorigenic tissues. The assays can be used to monitor the treatments with drugs that act on the pentose phosphate pathway in tumorigenic as well as non-tumorigenic tissues and organs. The assays of the invention are amenable to frequent sampling and measuring of the enzymatic activities in a treated patient over time.

5 [0036] In one embodiment, the invention provides a method for determining the activity of a TPP utilizing enzyme comprising the step of monitoring the production of NADH, e.g., conversion of NAD to NADH, by fluorescence. In various embodiments, the enzyme is transketolase, alpha-ketoglutarate dehydrogenase or pyruvate dehydrogenase. In some embodiments, the activity is measured from homogenized tissue samples without isolating cell components. The samples may be tumors, blood and other tissues, fresh or frozen, without further purification.

10 [0037] The invention also provides a method for determining the activity of an enzyme in an oxidative ribose-5-phosphate generating pathway, comprising the step of monitoring production of NADPH, e.g., conversion of NADP to NADPH, by fluorescence. In some embodiments, the enzyme is glucose-6-phosphate dehydrogenase (G6PDH).

20 [0038] In either the above-described methods, fluorescence is measured with excitation at about  $340 \pm 30$  nm and emission measured at about  $460 \pm 30$  nm in kinetic mode. In some embodiments, the activity is measured in homogenized cell samples without isolating cell components. In certain embodiments, the samples are tumor cells selected from the group of transformed cell lines, fresh or frozen tumor cells or tissues. The assay is most preferably performed on human tumor cells of any type. Preferably, the assay is performed in multi-well dishes.

25 Preferably, the amount of total protein per assay is less than about 80 micrograms.

[0039] The methods of the invention are advantageous over previously used methods because lysate clearance, for example by centrifugation or filtration, is not required. As a result, the assays of the invention are faster and more convenient and avoid possible enzyme loss and degradation during lengthy sample manipulations. Further, because the methods of the invention use fluorescence read out instead of absorption, they are more sensitive. Further, according to the

30

methods of the invention, turbidity and air-bubbles do not affect the reading and thus allow for accurate data acquisition in a more robust and high throughput fashion. The amount of sample required for accurate measurement is very small: (approximately 40  $\mu$ l of blood and < 1 mg of tissue). The small volume

5 requirement of the assays of the invention enables the skilled worker to study precious clinical samples, such as biopsies. Moreover, assays of the invention can be easily adapted to 96-well (or higher) format as described below in the Examples. These features make the assays of the present invention practical for drug discovery, and preclinical and clinical uses.

10 **[0040]** Assays of the invention may be used to optimize drug dosing in animal studies and during human clinical trials or therapy. Pharmacodynamic (PD) profiling via enzymatic activity is a better indicator for dosing regimen than the traditional pharmacokinetic (PK) profiling. Blood can be used as the most convenient sample for measuring drug exposure and PD properties. When tumor  
15 biopsy samples are available, either before, during or after a treatment regimen, they can be used to assess the effectiveness of the treatment. The course of treatment of hematological tumors can be followed by monitoring transketolase activity of the malignant cells. For preclinical studies using animal models, all tissues can be collected to study drug exposure and PD profile, selectivity against  
20 other TPP-utilizing enzymes, brain penetrance, and the like.

#### Monitoring Therapeutic Treatment

**[0041]** The assays and methods of the invention are useful for optimizing  
25 therapeutic dosing and/or scheduling of TPP mimetic drugs by sampling and monitoring enzymatic levels of TPP utilizing enzymes in oxidative and non-oxidative pathways in the treated patient over time. For example, if a TPP mimetic drug, such as N3PT, is administered to a patient to treat a tumor, whole blood and/or a tumor biopsy can be taken from the patient at one or more times after  
30 treatment and the enzymatic activities of various TPP utilizing enzymes in the samples measured using one or more assays of the invention (see, e.g., **Example 1**).

[0042] The assays of the present invention, thus, enable the skilled worker to assess the efficacy of the treatment. The assays can also be used to monitor and, if necessary, modify the treatment regimen. This enables the health care provider to monitor and make dosing/scheduling corrections earlier than and in a more systematic manner than with conventional methods for monitoring tumor treatment.

[0043] Accordingly, in another embodiment, the invention provides a method for monitoring the effectiveness of a TPP mimetic drug treatment in a patient in need thereof, by measuring the activity of a TPP utilizing enzyme in the blood or other tissue of the patient. In preferred embodiments, the method measures the production of NADH by fluorescence. In particularly preferred embodiments, fluorescence is measured with excitation at about  $340 \pm 30$  nm and emission is measured at about  $460 \pm 30$  nm in kinetic mode. In some embodiments, the TPP utilizing enzyme activity is measured in a tumor biopsy or blood sample of the patient before, during or after the drug treatment. In some embodiments, the TPP utilizing enzyme is transketolase, alpha-ketoglutarate dehydrogenase or pyruvate dehydrogenase.

#### Assays for Identifying TPP Mimetics Having Desirable Therapeutic Properties

[0044] The assays of the invention also are useful for identifying inhibitors of TPP utilizing enzymes. The ability of a candidate compound to inhibit the activity of one or more TPP utilizing enzymes can be determined according to the methods of the invention by detecting reduced enzymatic activity in cells or tissues after treatment with the candidate compound. The selectivity of a compound shown to be an inhibitor for a particular TPP utilizing enzyme can be determined by comparing the relative inhibition of other TPP utilizing enzymes. Inhibition of TK by new TPP mimetics can be further characterized using a competitive binding assay in which TK inhibition is reduced by thiamine in a concentration dependent manner, where high levels of thiamine overcome the effect of inhibition by the tested compound. The desirability of the specificity and affinity of TK inhibition by various TPP mimetics can be determined by comparing and contrasting these

results with the effects of N3PT in the thiamine competition assay. The results of these assays enable the skilled worker to assess the therapeutic properties of additional known or novel TPP-derived inhibitors in an efficient and reliable manner. The assays and methods of the invention are, therefore, a practical tool  
5 for determining the clinical application of known or novel compounds in the treatment of conditions that may benefit from transketolase inhibition, including but not limited to cancer.

[0045] Thus, the invention also provides methods for identifying a TPP mimetic drug for use as a therapeutic agent comprising the step of comparing the inhibition  
10 of a TPP utilizing enzyme by a test compound with the inhibition by N3PT. In one embodiment, the TPP utilizing enzyme is transketolase. In a preferred embodiment, the inhibition of the TPP utilizing enzyme is determined by monitoring the production of NADH or NADPH by fluorescence. In some embodiments, inhibition of the TPP utilizing enzyme is measured by competitive  
15 binding of the candidate compound in the presence of N3PT or thiamine. The following are examples which illustrate various aspects of the invention. These examples should not be construed as limiting. The examples are included for the purposes of illustration only.

20 **EXAMPLE 1**  
**Method for Determining Enzyme Activity in Blood, Tumors and Other Tissues**

[0046] Blood samples from mice were taken (40  $\mu$ l whole blood) serially or from  
25 mice sacrificed at the end of the experiment. Tissues, such as tumors (e.g. from implantation, xenograft, or arising spontaneously), brain, heart, kidney, liver, lung and spleen were taken and flash frozen in liquid nitrogen or on dry ice and stored in -80°C until time of assay. Four volumes of cold lysis buffer (20 mM HEPES, pH 7.5, 1mM EDTA, 0.2g/l Triton X-100<sup>®</sup> and 0.2g/L sodium deoxycholate,  
30 supplemented with 1mM DTT and 1mM PMSF just before use) were added to the blood, which was dissolved by vortexing. For blood that was frozen before coagulation, a clear lysate was obtained. If coagulation occurred, homogenization was used as described below for tissue. Tissues were suspended in lysis buffer in

10 ml round bottom tubes and homogenized with PowerGen 125<sup>®</sup> (Fisher Scientific) for four seconds at highest power while submerged in an ice-water bath. This step was repeated after a few seconds, as necessary. The lysate was used right away or else flash frozen and stored at -80°C until assay time. Eighty microliters (80  $\mu$ l) of lysate (containing 5 mg tissue/ml lysate for TK and kGDH, 0.5 mg/ml for G6PDH) were put directly in individual wells of a 96-well clear-bottomed assay plate. Twenty microliters (20  $\mu$ l) of 5x reaction mix was added to initiate each enzymatic reaction.

[0047] Each reaction was monitored for the appearance of NADH ( for transketolase, alpha-ketoglutarate dehydrogenase, pyruvate dehydrogenase) or NADPH (for glucose-6-phosphate dehydrogenase) at room temperature in a fluorescent plate reader with excitation at 340 nM and emission at 470 nM in kinetic mode. The velocity was determined by the slope of the initial linear range of increasing fluorescence, expressed in fluorescent units (FU)/min. The protein concentration in the lysate was determined using Bradford assays (BioRad) with BSA as a standard. The enzymatic velocity was normalized by the total protein concentration for inter-sample comparison. To obtain reliable results across samples, similar starting protein concentrations were prepared (within approximately 30%) so that the normalized velocity required only small adjustments. This was achieved by weighing the tissue and putting in lysis buffer so that the suspensions contained the same amount of tissue/ml lysis buffer for all samples.

The 5x reaction mixes for each enzyme were as follows:

[0048] For TK, the final concentrations were (following the addition of 80  $\mu$ l of lysate and 20  $\mu$ l of 5x reaction mix): 50 mM HEPES, pH 7.5, 40 mM KCl, 2.5 mM MgCl<sub>2</sub>, 1mM DTT, 5 mM NaArsenate, 0.5 mM NAD, 0.5 mM of ribose-5-phosphate mix, 2 unit/ml of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). See **Figure 1** for the reaction scheme.

[0049] For alpha-ketoglutarate dehydrogenase (kGDH), the final concentrations were: 50 mM HEPES, pH 7.5, 40 mM KCl, 2.5 mM MgCl<sub>2</sub>, 5 mM DTT, 2 mM  $\alpha$ -ketoglutarate acid, 0.5 mM NAD, 0.15 mM CoA.

The reaction scheme is:

### kGDH



[0050] For pyruvate dehydrogenase (PDH), the final concentrations were: 50 mM HEPES, pH 7.5, 40 mM KCl, 2.5 mM MgCl<sub>2</sub>, 5 mM DTT, 2 mM pyruvate, 0.5 mM NAD, 0.15 mM CoA.

The reaction scheme is:

### PDH



10

[0051] For glucose-6-phosphate dehydrogenase (G6PDH), the final concentrations were: 50 mM Tris-HCl, pH 8.1, 1mM MgCl<sub>2</sub>, 1mM DTT, 0.2 mM NADP, 0.5 mM glucose-6-phosphate.

The reaction scheme is:

15

### G6PDH



One more NADPH is generated from further oxidation of 6- phosphoglucono-lactone by enzymes present in the cells.

20

## EXAMPLE 2

### Method for Determining In Vivo Enzyme Inhibition

[0052] To investigate the amount of in vivo enzyme inhibition following treatment with an inhibitor, we administered a single dose of N3PT (100 mg/kg, intraperitoneally [i.p.]) and blood, spleen and brain samples were collected at various times from 0-120 hours after dosing. The enzymatic activities were determined as described in Example 1. TK activity was measured in blood and spleen. Because TK activity in the brain is below the detection limit of the assay, kGDH activity was measured in brain samples. Measurements were taken at various time intervals

30

[0053] As shown in Figure 2, using the above-described assay, inhibition of transketolase activity in the blood was readily detectable with 80% inhibition being detected at the nadir (12 hours) (**Figure 2**). Transketolase inhibition was



detectable in this assay at 1 hour post-treatment and was still evident at the final sampling at 120 hours (5 days). Inhibition of transketolase activity of up to 35% at 8-24 hours post-treatment was detected in the spleen. Brain transketolase activity was below the detection limit. No significant inhibition of brain kGDH activity was observed, indicating that N3PT has little or no significant brain penetration after a single dose.

[0054] We measured enzyme activity in an expanded panel of tissues from mice treated with N3PT or OxyT for 11 days i.p., twice per day. Samples were taken from tumors, blood, brain, heart, kidney, liver, lung and spleen, and TK, kGDH and G6PDH activities were determined as described above.

[0055] As shown in **Figure 3**, we detected the percent inhibition of TK activity in tumors after N3PT dosing (70%), and after OxyT (40%), both as compared to control (vehicle only) using the above-described assay. Inhibition was most pronounced in blood and kidney, followed by spleen and lung. By contrast, liver enzymatic activity was hardly affected. TK levels in the brain and heart were below the detection limit in both experimental conditions as well as in controls. As shown in **Figure 4**, kGDH activities were generally less affected than TK except in blood, where it was also obliterated. One can also measure the brain exposure of the compounds via kGDH. These results show that N3PT can inhibit the activity of both TK and kGDH. As G6PDH does not use TPP as co-factor, it was unlikely to be affected directly by TPP mimetics. Indeed, as shown in **Figure 5**, no significant decrease in enzymatic activity was observed following treatment with either oxythiamine or N3PT. The G6PDH activity measured, therefore, served as internal controls for sample integrity.

### EXAMPLE 3 Cell-Based Enzyme Activity Assay

[0056] To determine the activity of various TPP utilizing enzymes in human tumor cells and cell lines, we cultured cells including HCT116 (human colon carcinoma cells having an activated *K-ras* gene, *K-ras*<sup>G13D</sup>); HT1080 (human fibrosarcoma cells); DLD1 (colon adenocarcinoma), Rv22 (prostate carcinoma), HCT115 (colon carcinoma), MIA PA CA-2 (pancreas carcinoma), SK-Mel-5

(melanoma) National Cancer Institute [NCI]) and murine cancer lines: LLC (Lewis lung carcinoma), 4T1(breast carcinoma), and CT26 (colon carcinoma), all available from the American Type Culture Collection [ATCC] unless otherwise specified) in standard conditions (37°C, 5% CO<sub>2</sub>) in DMEM media (10% FBS, 1% Penicillin-Streptomycin) and harvested at 60-80% confluency by trypsinization. Approximately 2 million cells were collected in Eppendorf tubes and washed 2 times (2x) with PBS by centrifugation and stored at -20°C as cell pellets. Ice-cold lysis buffer (1 ml) (20 mM HEPES, pH 7.5, 1mM EDTA, 0.2g/l Triton X-100 and 0.2g/L sodium deoxycholate, supplemented with 1mM DTT and 1mM PMSF just before use) was added to the cell pellet. Cells were lysed by vortexing. Lysate containing different amounts of cells were brought up to a volume of 80 µl with lysis buffer and were mixed with 20 µl of the 5x reaction mix described in **Example 1** in a clear bottomed 96-well assay plate.

**[0057]** The reactions were monitored in a fluorescent plate reader and enzymatic velocity was determined as described above. TK activities could be measured using lysate from ≥5000 cells in most cell lines tested. However, in cell lines over expressing TK, the detection limit could be as low as 250 cells. **Figure 6** shows the TK activity and the detection limit (in cell number).

**[0058]** kGDH activity could be determined using ≥10000 cells in most cell lines tested. **Figure 7** shows the kGDH activity in various cell lines with (HCT116-TK, HT1080-TK) and without (HCT116, HT1080, DLD-1, HuCa25 (22Rv1)) over expressed TK. Enzymatic kGDH activity is plotted as the detected fluorescence against the number of cells.

**[0059]** **Figure 8** shows the G6PDH activity. G6PDH had the highest enzymatic activity in the cells, can be determined using as little as 250 cells.

**[0060]** The enzymatic activities could also be measured in 96-well plates directly. Adherent cells were plated in clear-bottomed 96-well cell culture plates, allowed to attach and grown until the cell density reached about 60-80% confluency. Plates were inverted to remove media and blotted on paper towels to remove residual media. Plates were stored at -20°C or immediately assayed for enzymatic activity. 80 µl of lysis buffer was added to each well, and the cells incubated at RT for 10 min to allow cell lysis. After lysis, 20 µl of the

aforementioned 5x reaction mix was added to each well to initiate the reaction. Reactions were monitored as described above.

#### EXAMPLE 4

##### **Determining Inhibition Constants of TPP Mimetics for TK, kGDH and PDH Activities**

- 5 [0061] We determined the  $IC_{50}$  of compounds that inhibit the activity of the TPP utilizing enzymes TK, kGDH and PDH in a convenient 96-well format using an optimized version of the method described in the previous Examples.
- 10 [0062] The high thiamine levels in conventional cell culture media (e.g., DMEM (12  $\mu$ M) , RPMI (3  $\mu$ M)) masks the inhibitory effect of such inhibitors. To measure the  $IC_{50}$  of such inhibitors, thus, a thiamine depleted DMEM, containing all the ingredients of normal DMEM except for thiamine (HyClone, custom order),
- 15 was used. Thiamine-depleted media (TDM) is made up with thiamine-depleted DMEM, 10% FBS, which contains negligible amount of thiamine (estimated to be ~3-5% nM) and 1% Penicillin-streptomycin.
- [0063] Log-phase growing cells were trypsinized and resuspended in TDM. Optimization of the initial cell counts is recommended for each cell line to ensure
- 20 that enzyme activity can be observed at the beginning and that healthy growth can continue. For cell lines that have a doubling time of approximately 24 hours and cellular transketolase levels high enough to be reliably detected with five thousand (5K) cells such as HCT116 and HT1080, 8K cells are recommended. Using this guide,  $IC_{50}$ s could be monitored for 6 days and 2-4 days of treatment resulted in a
- 25 value that was stable and reproducible.
- [0064] Media containing 8K cells (95  $\mu$ l) were used to seed individual wells in a 96-well clear-bottom cell cultured treated sterile plate. Inhibitor compounds were dissolved in 100% DMSO as 10 mM solutions. Serial dilutions were then made in 100% DMSO to make up a 100X stock, then diluted to 20X in double-deionized
- 30 H<sub>2</sub>O (ddH<sub>2</sub>O). Twenty-four hours after seeding, 5  $\mu$ l of 20x inhibitor compound stock solution was added to the cells so that the final concentration of DMSO is 1%. Media were changed after 24 hours. Forty-eight hours after inhibitor compound treatment, the plates were inverted to remove media and blotted on a paper towel. The plates were then either subjected to enzymatic reactions

immediately or were frozen at -20°C for future assays. Enzymatic reactions were carried out as described in the previous Examples. Enzymatic inhibition was expressed as percent of control wells that were not treated with compounds. The values (y) were plotted as function of the log concentration (x) and fitted to a sigmoidal dose-response curve with variable slopes that bears the equation:

$y = \text{bottom} + (\text{top} - \text{bottom}) / (1 + 10^{((\log EC_{50} - x) * \text{hillslope}))}$ .

[0065] Results shown in **Figure 9** indicate that the slow off-rate of the inhibitor compounds preserves enzymatic inhibition in cell lysates. Results shown in **Figure 10** indicate that the IC<sub>50</sub> of N3PT for both TK and kGDH was 20 nM and 86 nM respectively. Therefore, N3PT inhibits the activity of both TK and kGDH but is a more potent inhibitor for TK than kGDH.

#### **EXAMPLE 5**

##### **Cell-based Enzyme Assay for inhibitors of Substrate Binding**

[0066] Inhibitors for the substrate binding site are generally reversible with a fast off-rate. Dilution with assay buffers and the use of the detergents affect the enzyme-inhibitor complex and are, thus, unsuitable for an assay involving substrate inhibitors. To determine the effects of these types of inhibitors, a new method was devised. Xylulose has been shown to cause a temporary increase in sedoheptulose-7-phosphate in hepatocytes (Vincent et al. "D-xylulose-induced depletion of ATP and Pi in isolated rat hepatocytes". *FASEB J.*, 3: 1855-1861 (1989)).

[0067] Human tumor cells and cell lines were first cultured as described in **Example 3** and plated in normal media. The following day, xylulose was added to each use to achieve a final concentration of 1mM. The media was then removed and 50 µl of 50% acetonitrile solution was added to the cells and the amount of sedoheptulose-7-phosphate was quantified by liquid chromatography mass spectrometry (LCMS). IC<sub>50</sub> values were derived in the same fashion as described in previous Examples, except the relative amount of sedoheptose-7-phosphate is used rather than velocity of enzymatic activity.

## EXAMPLE 6

### Method for Characterizing N3PT as a Competitive Inhibitor of Transketolase

[0068] HCT116 cells were plated in clear-bottomed 96-well culture plates, at a  
5 density of 8000 cells/well in TDM. The following morning, N3PT and different  
amounts of thiamine (12  $\mu$ M, 2.4  $\mu$ M, 0.48  $\mu$ M, 0.096  $\mu$ M, 0.0192  $\mu$ M, 0  $\mu$ M) were  
added to the cells. Forty-eight hours later, plates were inverted to remove media  
and blotted on paper towels to remove residual media. Plates were immediately  
assayed for enzymatic TK activity. 80  $\mu$ l of lysis buffer was added to each well,  
10 and the cells incubated at RT for 10 min to allow cell lysis. After lysis, 20  $\mu$ l of  
the aforementioned 5X reaction mix was added to each well to initiate the reaction.  
Reactions were monitored as described above.

[0069] The inhibitory effect of N3PT on TK activity was measured in the  
presence of increased concentrations of thiamine, as shown in **Figure 11**.  
15 Inhibition of TK by N3PT was reduced by thiamine in a concentration dependent  
manner, where high levels of thiamine (e.g., 12  $\mu$ M) were shown to overcome  
N3PT inhibition.

[0070] Additional time course experiments revealed that the inhibitory effect of  
N3PT on cellular TK activity persisted for several days, as depicted in **Figure 12**.  
20 Cells were plated in TDM media 24 hours earlier, different concentration of N3PT  
and 100 nM thiamine were added to the cells and treated for 48 hour to allow  
N3PT to exert its inhibitory effect (day 2; d2). The media was then changed to  
contain only 100 nM thiamine and one plate was assayed every day for the next  
five days (d3 to d7). At the end of study on day 7 (d7), TK activity had not fully  
25 recovered. These results demonstrate that the inhibitory effect of N3PT can persist  
for many days.

What is embodied is:

1. An assay for determining the activity of a TPP utilizing enzyme comprising the step of monitoring production of NADH by fluorescence.
2. The assay of embodiment 1, wherein the TPP utilizing enzyme is transketolase, alpha-ketoglutarate dehydrogenase or pyruvate dehydrogenase.  
5
3. The assay of embodiment 1, wherein the activity is monitored by GAPDH-catalyzed conversion of NAD to NADH, resulting in the production of fluorescent NADH,
4. The assay of embodiment 1, wherein the activity is  
10 measured from homogenized cell samples without isolating cell components.
5. The assay of embodiment 4, wherein the samples are tumors, blood and tissues, fresh or frozen, without further purification.
6. An assay for determining the activity an enzyme in an oxidative ribose-5-phosphate generating pathway, comprising the step of.  
15 monitoring production of NADPH by fluorescence.
7. The assay of embodiment 6, wherein the enzyme is glucose-6-phosphate dehydrogenase.
8. The assay of embodiment 6, wherein the activity is monitored by G6PDH-catalyzed conversion of NADP to NADPH, resulting in the  
20 production of fluorescent NADPH,
9. The assay of embodiment 6, wherein activity is measured from homogenized cell samples without isolating cell components.
10. The assay of embodiment 9, wherein the samples are tumor cells selected from the group of transformed cell lines, fresh or frozen tumor cells  
25 or tissues.

11. The assay of embodiment 1 or 6, performed on human tumor cells.
12. The assay of embodiment 1 or 6, performed in multi-well dishes.
- 5 13. The assay of embodiment 1 or 6, wherein the assay is cell-based.
14. The assay of embodiment 1 or 6, wherein fluorescence is measured with excitation at about  $340 \pm 30$  nm and emission measured at about  $460 \pm 30$  nm in kinetic mode.
- 10 15. The assay of embodiment 1 or 6, wherein the amount of total protein per assay is less than about 80 micrograms.
16. A method for monitoring the effectiveness of a TPP mimetic drug treatment in a cancer patient, comprising the step of measuring the activity of a TPP utilizing enzyme by monitoring the production of NADH by fluorescence.
- 15 17. The method according to embodiment 16, wherein the activity is measured by sampling a tumor biopsy or whole blood of the patient before, during or after said drug treatment.
18. The method according to embodiment 16, wherein the measurement of said activity can be used to modify said drug treatment in the
- 20 patient.
19. The method according to embodiment 16, wherein the drug treatment is optimized through recurring measurements of said activity in a patient.
20. The method according to embodiment 16, wherein the TPP utilizing enzyme is transketolase, alpha-ketoglutarate dehydrogenase or pyruvate
- 25 dehydrogenase.

21. The method according to embodiment 16, wherein the activity is monitored by GAPDH-catalyzed conversion of NAD to NADH, resulting in the production of fluorescent NADH,

22. The method according to embodiment 16, wherein  
5 fluorescence is measured with excitation at about  $340 \pm 30$  nm and emission measured at about  $460 \pm 30$  nm in kinetic mode.

23. A method for identifying a TPP mimetic drug for use as a therapeutic agent comprising the step of comparing the inhibition by N3PT of a TPP utilizing enzyme with the inhibition by a test TPP mimetic drug.

10 24. The method according to embodiment 23, wherein the inhibition of the TPP utilizing is determined by monitoring the production of NADH by fluorescence.

25. The method according to embodiment 24, wherein the activity is monitored by GAPDH-catalyzed conversion of NAD to NADH,  
15 resulting in the production of fluorescent NADH.

26. The method according to embodiment 23, wherein the inhibition of the TPP utilizing enzyme is measured by competitive binding in the presence of N3PT or thiamine.


27. The method according to any one of embodiments 23-26,  
20 wherein the TPP utilizing enzyme activity is transketolase.




ABSTRACT

**[0001]** The invention provides improved methods for measuring enzymatic activities involved in the oxidative and non-oxidative pentose phosphate pathways, and other thiamine pyrophosphate containing enzymes, which are commonly  
5 elevated in tumor cells. The assays of the invention are useful for optimizing therapeutic dosing and scheduling of drugs acting on the pentose phosphate pathways by sampling and monitoring enzymatic levels in a treated patient over time. Finally, the assays are useful for identifying and characterizing compounds having beneficial therapeutic effects.


**Figure 1**




**Figure 2**



**Figure 3**



**Figure 4**



**Figure 5**






Figure 6



**Figure 7**





**Figure 8**






Figure 9



**Figure 10**



	TK	kGDH
BOTTOM	-0.37	-1.22
TOP	76.08	100.20
HILLSLOPE	0.91	0.73
EC50	0.007	0.086

Figure 11





Figure 12



## INVENTOR INFORMATION

Inventor One Given Name:: May  
Family Name:: Han  
Postal Address Line One:: 46 Browne Street, Apt. 3  
City:: Brookline  
State or Province:: MA  
Country:: U.S.A.  
Postal or Zip Code:: 02446  
Citizenship Country:: P.R. China

## CORRESPONDENCE INFORMATION

Correspondence Customer Number:: 1473  
Fax One:: 212-596-9090  
Electronic Mail One:: bruskin@fishneave.com

## APPLICATION INFORMATION

Title Line One:: METHODS FOR MEASURING ENZYME ACTIVITIES  
Title Line Two:: IN CELLS, BLOOD, TUMORS AND TISSUES  
Total Drawing Sheets:: 12  
Formal Drawings?: No  
Application Type:: Provisional  
Docket Number:: GEN/033PROV  
Secrecy Order in Parent Appl.?: No

## REPRESENTATIVE INFORMATION

Representative Customer Number:: 1473  
Registration Number One:: 27794  
Registration Number Two:: 38479  
Registration Number Three:: 39350

Source:: PrintEFS Version 1.0.1